204 related articles for article (PubMed ID: 32632925)
1. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
2. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
3. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
4. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Duintjer Tebbens RJ; Thompson KM
Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
[TBL] [Abstract][Full Text] [Related]
5. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
[TBL] [Abstract][Full Text] [Related]
6. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
Thompson KM; Kalkowska DA; Badizadegan K
Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
[TBL] [Abstract][Full Text] [Related]
7. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
8. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
9. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198
[TBL] [Abstract][Full Text] [Related]
10. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
11. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
[TBL] [Abstract][Full Text] [Related]
12. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
[TBL] [Abstract][Full Text] [Related]
13. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Duintjer Tebbens RJ; Thompson KM
BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
[TBL] [Abstract][Full Text] [Related]
14. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
[TBL] [Abstract][Full Text] [Related]
15. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
Kalkowska DA; Wassilak SG; Wiesen E; F Estivariz C; Burns CC; Badizadegan K; Thompson KM
Gates Open Res; 2023; 7():55. PubMed ID: 37547300
[No Abstract] [Full Text] [Related]
16. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
17. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
18. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Thompson KM; Kalkowska DA
Risk Anal; 2021 Feb; 41(2):229-247. PubMed ID: 32339327
[TBL] [Abstract][Full Text] [Related]
19. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
20. [Advances in researches of serotype 2 novel oral polio vaccine].
Chen SY; Li Y; Yang JS; Yin XX
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):413-417. PubMed ID: 33730837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]